Monitor for the final European Commission decision expected in Q2 2026, which could trigger positive price movement. The approval would open a new market for Joenja as the first treatment for APDS in Europe.
Price Chart
Executive Summary
Pharming Group received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta (PI3K) syndrome (APDS) in adult and pediatric patients 12 years and older. If approved by the European Commission, Joenja would become the first approved treatment for APDS in the European Union.
Key Facts
- CHMP adopted a positive opinion recommending marketing authorization for Joenja (leniolisib) for APDS treatment
- Final European Commission decision expected in Q2 2026
- If approved, Joenja would be the first treatment for APDS in the EU
- Approval would be valid in all 27 EU member states plus Norway, Iceland, and Liechtenstein
- Joenja is already approved in the US, UK, Japan, Australia, and Israel
- Decision based on Phase III clinical trial data showing statistically significant impact
Financial Impact
Potential for significant revenue growth if approved in EU market
Risk Factors
- European Commission could reject the recommendation despite positive CHMP opinion
- Commercial uptake may be limited due to APDS being a rare disease affecting 1-2 people per million
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000012 |
| Document: 0001828316-26-000012-index-headers.html | 0001828316-26-000012 |
| Document: 0001828316-26-000012-index.html | 0001828316-26-000012 |
| Document: 0001828316-26-000012.txt | 0001828316-26-000012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 6-K | $11.21 $10.55 | ▼ −5.89% | ▼ −5.67% | $9.75 (−13.02%) |
Aug 13, 2026 7w ago | 6-K | $12.35 $11.68 | ▼ −5.43% | ▼ −3.46% | $9.75 (−21.05%) |
Jun 4, 2026 17w ago | 6-K | $12.47 $12.88 | ▲ +3.29% | ▲ +5.84% | $9.75 (−21.81%) |
May 28, 2026 18w ago | 6-K | $13.66 $12.24 | ▼ −10.40% | ▼ −10.35% | $9.75 (−28.62%) |
May 22, 2026 19w ago | 6-K | $13.62 $12.28 | ▼ −9.84% | ▼ −11.05% | $9.75 (−28.41%) |
Apr 16, 2026 24w ago | 6-K | $17.33 $16.64 | ▼ −3.98% | ▼ −4.97% | $9.75 (−43.74%) |
Mar 27, 2026 27w ago | 6-K | $16.31 $16.50 | ▲ +1.16% | ▼ −2.70% | $9.75 (−40.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access